On June 23, 2021, Lyndra Therapeutics, Inc. closed the transaction. The company received $60,500,000 in the round led by new investor AIG Investments, Ltd. The transaction included participation from new investors Yipinhong Pharmaceutical (USA) Limited, Limitless Earth plc, and The Catalytic Impact Foundation, Inc. through ImpactAssets and returning investors Polaris Partners, The Invus Group, LLC, Quark Venture Inc., Partners Innovation Management Co., LLC, HOPU Jinghua (Beijing) Investment Consultancy Co., Ltd., and Gilead Sciences, Inc. The company received $60,470,112 pursuant to exemption provided under Regulation D from 22 investors.